Farmer DT , Patel P, Choi R, Liu CY, Crump JG
May 2013
From the six major immune checkpoints for cancer immunotherapy, namely cytotoxic T-lymphocyte associated protein 4 (CTLA-4), programmed cell death 1 (PDCD1), cluster of differentiation 274 (CD274), inducible T-cell costimulator (ICOS), lymphocyte-activation gene 3 (LAG3), and CD40, ipilimumab targeted against CTLA-4 was the first monoclonal antibody approved by the Food and Drug Administration (FDA) in 2011
This single habit prevents the most catastrophic dosing errors
Senolytics have been developed to selectively target senescent cells as an alternative therapeutic approach, and have been found to successfully clear senescent cells whilst also reducing cancer relapse and improving the treatment-damaged environment (Demaria et al., 2017
New: Book online at Hello Gorgeous through Square same-day confirmations & reminders